Bristol-Myers Squibb-Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note

Company Performance - Bristol Myers Squibb (BMY) closed at $60.18, with a daily increase of +0.6%, outperforming the S&P 500's loss of 1.78% [1] - Over the past month, BMY shares gained 0.18%, while the Medical sector increased by 0.26% and the S&P 500 decreased by 3.48% [1] Financial Projections - The upcoming earnings per share (EPS) for Bristol Myers Squibb is projected at$ 1.55, representing a significant increase of 135.23% from the same quarter last year [2] - Revenue is estimated to be $10.69 billion, reflecting a decline of 9.94% compared to the equivalent quarter last year [2] Annual Estimates - For the entire year, earnings are forecasted at$ 6.75 per share, indicating a remarkable increase of 486.96%, while revenue is projected at $45.59 billion, showing a decrease of 5.6% compared to the previous year [3] Analyst Sentiment - Recent changes to analyst estimates for Bristol Myers Squibb reflect evolving short-term business trends, with positive revisions indicating analyst optimism about the company's profitability [3][4] Zacks Rank and Performance - The Zacks Rank system, which evaluates estimate changes, currently ranks Bristol Myers Squibb at 3 (Hold), with the consensus EPS estimate moving 3.96% lower over the last 30 days [5] - Historically, 1 ranked stocks in the Zacks Rank system have yielded an average annual return of +25% since 1988 [5] Valuation Metrics - Bristol Myers Squibb has a Forward P/E ratio of 8.87, indicating a discount compared to its industry's Forward P/E of 19.4 [6] - The company has a PEG ratio of 2.22, while the Medical - Biomedical and Genetics industry has an average PEG ratio of 1.57 [7] Industry Context - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 66, placing it in the top 27% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]